Growth and fibrinolytic parameters of human umbilical vein endothelial cells seeded onto cardiovascular grafts  by Zhang, Jing Chuan et al.
GROWTH AND 
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It was the aim of this study to investigate possible effects of biomaterials used to 
produce vascular grafts on the fibrinolytic system of endothelial cells. Therefore 
growth conditions for human umbilical vein endothelial cells on polytetrafluoroeth- 
ylene and on polyurethane were optimized. Tissue culture polystyrene was used as a 
control material. We could demonstrate that precoating of the materials with 
fibronectin significantly increased the growth rate of human umbilical vein endo- 
thelial cells on these materials. Furthermore, we showed that human umbilical vein 
endothelial cells grown on polytetrafluoroethylene or polyurethane r leased more 
plasminogen activator inhibitor-1 and tissue type-plasminogen activator into the 
conditioned media than did human umbilical vein endothelial cells grown on tissue 
culture polystyrene. Human umbilical vein endothelial cells cultured on polytet- 
rafluoroethylene also deposited more plasminogen activator inhibitor-1 into the 
extracellular matrix than did control cells grown on tissue culture polystyrene. Our 
results give evidence that human umbilical vein endothelial cells grown on two 
biomaterials used to construct vascular grafts, namely polytetrafluoroethylene a d
polyurethane, produce tissue-type plasminogen activator as well as plasminogen 
activator inhibitor-l, two major components ofthe fibrinolytic system also expressed 
by endothelial cells in vivo. In conclusion, our data suggest hat endothelial cells 
grown on vascular grafts show functional integrity concerning their fibrinolytic 
system, which in turn might contribute to reduce the thrombogenic properties of the 
graft material. (J THORAC CARDIOVASC SURG 1995;109:1059-65) 
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A lthough blood compatibility of biomaterials has improved over the years, a nonthrombogenic 
surface has not  yet been found. The failure of many 
clinical implantation procedures is attributed to the 
early thrombogenicity of the graft surface and to the 
late development of initial hyperplasia nd down- 
stream atherosclerosis. 1' 2 Attempts to endothelialize 
synthetic graft surfaces of small-diameter vascular 
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prostheses to overcome their thrombogenic properties 
have been made. 3-8 Endothelial cells play a key role in 
the development and dissolution of thrombi. They 
produce urokinase-type lasminogen activator, tissue- 
type plasminogen activator, and their major physio- 
logic inhibitor, plasminogen activator inhibitor-1. 9 Tis- 
sue-type plasminogen activator, which activates the 
zymogen plasminogen to plasmin with much higher 
efficiency in the presence of fibrin, is thought to be 
mainly responsible for intravascular clot lysis, whereas 
urokinase-type plasminogen activator is involved in 
processes requiring extracellular proteolysis. 1°
The production of plasminogen activators and 
plasminogen activator inhibitor-1 by endothelial 
cells is regulated by a wide variety of stimuli, nq5 
whereby an increase in the production of tissue-type 
plasminogen activator would enhance the fibrino- 
lytic potential of these cells and an increase in 
plasminogen activator inhibitor-1 production would 
decrease the fibrinolytic potential of the endothe- 
lium, rendering it antifibrinolytic. Impaired fibrinol- 
ysis, on the other hand, is thought o predispose to 
thrombus formation and atherosclerosis. Functional 
properties of endothelial cells in culture are strongly 
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dependent on the extracellular matrix onto which 
cells had been seeded. Therefore functional proper- 
ties of endothelial cells are strongly influenced by 
the biomaterials used for vascular grafting and are 
of major importance for maintaining a nonthrom- 
bogenic surface. It was the aim of this report to 
study the fibrinolytic system of human endothelial 
cells seeded onto different biomaterials used for the 
production of vascular grafts and to investigate 
possible effects of  these materials on the fibrinolytic 
capacity of such endothelial cells. 
Materials and methods 
Cell culture. Human umbilical vein endothelial cells 
were isolated by mild collagenase treatment as de- 
scribed. 16 The endothelial cells were seeded into Petri 
dishes (Costar, Cambridge, Mass.) coated with 1% gelatin 
(Biorad, Richmond, Calif.) and grown to confluence in 
medium 199 (Sigma Chemical Co., St. Louis, Mo.) con- 
taining the following: 20% supplemented calf serum (Hy- 
Clone, Logan, Utah), penicillin 50 IU/ml, streptomycin 50 
/zg/ml, amphotericin B 250 ng/ml (all JRH Biosciences, 
Lenexa, Kan.), ECGS 50 /zg/ml (Technoclone, Vienna, 
Austria), and heparin 5 U/ml (Liquemin Roche, Hoff- 
mann-La Roche, Basel, Switzerland) in a humidified 
atmosphere of 95% air and 5% carbon dioxide at 37 ° C. 
Cells were confirmed to be endothelial cells by their 
typical cobblestone shape, 17 by positive immunofluores- 
cence with anti-von Willebrand factor antibodies (Cappel, 
Cochranville, Pa.), TM and by uptake of acetylated low- 
density lipoprotein. 19 All human umbilical vein endothe- 
lial cells used in this study were between passages 2 and 3. 
Graft materials. Polyurethane, which was kindly pro- 
vided by The Institute of Chemistry (Chinese Academy of 
Sciences, China), was purified by precipitation with meth- 
anol from a dimethylformamide solution and then dis- 
solved in dimethylformamide and cast into membranes on 
cover slips. Submerging the cover slips in water for 2 hours 
yielded polyurethane membranes. Reinforced thin-walled 
polytetrafluoroethylene patches, 0.1 mm, were purchased 
from W. L. Gore & Assoc. Ges.m.b.H. (Salzburg, Aus- 
tria). The surface of tissue culture polystyrene flasks 
(Costar) was used as control material. 
Precoating with fibronectin. Human fibronectin was 
isolated as described previously, z°Patches of polytetraflu- 
oroethylene and polyurethane, respectively, and tissue 
culture polystyrene 96 well plates (Costar) were coated 
with fibronectin in phosphate-buffered saline, pH 7.4, at 
the indicated concentrations for 30 minutes at 37 ° C. 
Thereafter the material was rinsed three times with 
phosphate-buffered saline and remaining binding sites 
were blocked by incubation at 4°C overnight with 1% 
bovine serum albumin in phosphate-buffered saline. After 
the material had been washed three times with phosphate- 
buffered saline containing 0.5% Tween 20 (Sigma), fi- 
bronectin binding was quantified by incubating the mate- 
rial for 2 hours at 37°C with a peroxidase-labeled 
monoclonal ntifibronectin antibody (2FN, Technoclone), 
which was labeled with peroxidase according to the pro- 
tocol of Nakane and Kawaoi .  za The surfaces were washed 
again and a 1 gm/L solution of 2,2'-azinobis(3-ethylbenz- 
thiazolinesulfonic a id) (Sigma) in sodium phosphate 0.11 
tool/L, citrate buffer 0.05 mol/L, pH 5.85, made 0.03% 
(vol/vol) in hydrogen peroxide, was added to the fibronec- 
tin-coated tissue culture polystyrene 96 well plates or to 
pieces of polytetrafluoroethylene or polyurethane cut to 
size (0.64 cm diameter) and placed into untreated 96 well 
plates. Absorbances at 405 nm (492 nm reference wave- 
length) were read with an Anthos Reader 2001 (Anthos, 
Austria). As a control, the same sequence was performed 
with uncoated polytetrafiuoroethylene, polyurethane, and 
tissue culture polystyrene. 
For cell growth experiments, tissue culture polystyrene 
96 well plates or patches of polyurethane and polytetraflu- 
oroethylene, which were sterilized and cut to size (0.64 cm 
diameter) and placed into 96 well plates were coated with 
fibronectin 10 /xg/cm 2 for 30 minutes at 37°C. The 
material was then rinsed three times with phosphate- 
buffered saline to remove nonbound fibronectin, and 
human umbilical vein endothelial cells were seeded onto 
the surfaces as described later. 
Seeding procedure and determination of growth of 
human umbilical vein endothelial cells. Human umbilical 
vein endothelial cells, grown to confluence in Petri dishes 
under conditions described earlier, were seeded into 
tissue culture polystyrene-96 well plates (Costar) or onto 
patches of polytetrafluoroethylene or polyurethane placed 
into 96 well plates at a density of 9 x 103 cells/cm z. Four 
days after the cells were seeded, cell numbers were 
determined with the EZ4U kit (Biomedica, Vienna, Aus- 
tria). 2z In brief, a 25 txl dye solution that becomes 
incorporated into ribosomes of live cells was added to the 
wells containing human umbilical vein endothelial cells 
and 200/~1 of regular growth medium. Thereafter the cells 
were incubated for 3 hours at 37 ° C and the absorbance at
a wavelength of 450 nm (620 nm reference wave length) 
was determined with an Anthos Reader 2001 (Anthos). A 
calibration curve was constructed by means of wells 
containing different numbers of human umbilical vein 
endothelial cells. The cell number in these wells was 
determined by staining the nuclei with crystal violet, z3 A 
linear correlation existed between absorbance values and 
the number of human umbilical vein endothelial cells in 
the respective wells (r = 0.98). 
Preparation of conditioned media and extracellular 
matrix. Confluent monolayers of human umbilical vein 
endothelial cells grown on polytetrafluoroethylene, poly- 
urethane, or tissue culture polystyrene as described were 
rinsed twice with Hanks balanced salt solution (Sigma). 
Thereafter medium 199 containing insulin 5 ~g/ml, trans- 
ferrin 5 tzg/ml, and sodium selenite 5 ng/ml (Sigma) was 
added to the cells. After the indicated time periods, 
conditioned medium of such cells was harvested, centri- 
fuged at 1000 g for 5 minutes to remove cell debris, and 
stored at -70 ° C. So that extracellular matrix could be 
obtained from these cells, the monolayers were washed 
three times with cold phosphate-buffered saline, pH 7.4. 
Thereafter the cells were lysed with 0.1% Triton X-100 
octyphenoxy polyethoxyethanol in phosphate-buffered sa- 
line, pH 7.4, and cellular components were removed by 
washing with distilled water. 
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Assays for tissue.type plasminogen activator, uroki- 
nase-type plasminogen activator, and plasminogen acti- 
vator inhibitor-1 antigen in conditioned medium. Tissue- 
type plasminogen activator, urokinase-type lasminogen 
activator, and plasminogen activator inhibitor-1 antigen in 
conditioned medium were determined by specific enzyme- 
linked immunosorbent assays (ELISAs) with monoclonal 
antibodies pecific for tissue-type plasminogen activator, 
urokinase-type plasminogen activator, and plasminogen 
activator inhibitor-1 (Technoclone). The test ranges for 
these assays are 0.3 to 2.5 ng/ml for tissue-type plasmin- 
ogen activator, 0.6 to 10 ng/ml for urokinase-type las- 
minogen activator, and 1.0 to 30.0 ng/ml for plasminogen 
activator inhibitor-1. The tissue-type plasminogen activa- 
tor ELISA detects free tissue-type plasminogen activator 
and tissue-type plasminogen activator in complex with 
plasminogen activator inhibitor-l; the urokinase-type 
plasminogen activator ELISA detects free urokinase- 
type plasminogen activator and urokinase-type lasmino- 
gen activator in complex with plasminogen activator in- 
hibitor-i; and the plasminogen activator inhibitor-1 
ELISA measures active, complexed, and latent plasmino- 
gen activator inhibitor-1. 
Determination of tissue-type plasminogen activator 
and plasminogen activator inhibitor-1 antigen in extra- 
cellular matrix. Extracellular matrix prepared as de- 
scribed earlier was incubated for 2 hours at 37 ° C with 100 
t*l/well peroxidase-labeled monoclonal antibodies against 
tissue-type plasminogen activator (MPW3VPA, Techno- 
clone) or plasminogen activator inhibitor-1 (3PAI5, Tech- 
noclone). Thereafter, the extracellular matrix was washed 
three times with 300/xl/well of phosphate-buffered saline, 
pH 7.4, containing 0.5% Tween 20 (Sigma), and 100 
/A/well of 2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid) 
in sodium phosphate 0.11 tool/L, citrate buffer 0.05 mol/L, 
pH 5.85, made 0.03% (vol/vol) in hydrogen peroxide, was 
added. As a control, the materials coated with gelatin 
were processed as described earlier. Absorbanees were 
read at 405 nm (492 nm reference wavelength). Absor- 
bances obtained with the gelatin-coated materials were 
deducted from the absorbance values obtained with the 
respective xtracellular matrix to correct for nonspecific 
binding of the monoclonal antibody. Nonspecific binding 
was less than 10%. 
Statistical analysis. Values are given as means +_ stan- 
dard deviation. Analysis of variance was performed to 
statistically compare cell proliferation and production of 
fibrinolytic omponents of the three experimental groups. 
When only two groups were compared, a Student's t test 
for unpaired observations was performed. 
Results 
When polytetrafluoroethylene was coated with 
increasing concentrations of fibronectin, a dose- 
dependent increase in the cell number of human 
umbilical vein endothelial cells determined 4 days 
after seeding was seen (Fig. 1). Maximal increase in 
cell proliferation was seen from a 5/ ,g/cm 2concen- 
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Fig. 1. The effect of fibronectin coating concentration  
growth of human umbilical vein endothelial cells. Human 
umbilical vein endothelial cells were seeded on polytet- 
rafluoroethylene coated with different concentrations of
fibronectin (0.5 to 30.0/~g/cm 2) at a density of 9 × 103/cm 2 
and counted 4 days after seeding, as described in the 
Materials and methods ection. The data represent mean 
values + standard eviations of three independent exper- 
iments. Nine pieces of the biomaterial were used. Inset: 
Fibronectin binding capacity of polytetrafluoroethylene, 
polyurethane, and tissue culture polystyrene. The material 
was coated with fibronectin (10 /,Lg/cm2). F ibronect in  
binding was determined with a peroxidase-labeled mono- 
clonal antifibronectin antibody as described in the Mate- 
rials and methods section. Values represent means -+ 
standard deviations of three independent experiments. 
Nine pieces of the biomaterials were used. FN, Fibronec- 
tin; PTFE, polytetrafluoroethylene; PU, polyurethane; 
TCP, tissue culture polystyrene. 
the inset to Fig. 1, fibronectin coating efficiency was 
similar for all three materials tested. 
As can be seen from Fig. 2, coating with fibronec- 
tin significantly increased the proliferation of human 
umbilical vein endothelial cells on polytetrafluoro- 
ethylene and polyurethane when compared with the 
untreated control. The proliferation rate of human 
umbilical vein endothelial cells was signifcantly 
higher on polyurethane than on polytetrafluoroeth- 
ylene or tissue culture polystyrene (p < 0.01). 
As can be seen from Fig. 3, a time-dependent 
increase in the number of human umbilical vein endo- 
thelial cells growing on polytetrafluoroethylene coated 
with fibronectin was paralleled by a time-dependent 
increase in tissue-type plasminogen activator antigen 
in the conditioned medium of these cells. 
Plasminogen activator inhibitor-1 antigen and 
tissue-type plasminogen activator antigen were de- 
termined in the conditioned medium of human umbil- 
ical vein endothelial cells grown on polytetrafluoroeth- 
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Fig. 2. Proliferation of human umbilical vein endothelial 
cells on polytetrafluoroethylene, polyurethane, and tissue 
culture polystyrene. Biomaterial surfaces were coated 
without or with fibronectin 10 txg/cm 2.Human umbilical 
vein endothelial cells were seeded at a density of 9 × 
103/cm a and counted 4 days after seeding as described in 
the Materials and methods ection. Cell numbers on each 
material were significantly different when compared with 
the two other materials (*p < 0.01). Values represent 
means _+ standard eviations of three independent exper- 
iments. Twelve pieces of the biomaterials were used. FN, 
Fibronectin; PTFE, polytetrafluoroethylene; PU, polyure- 
thane; TCP, tissue culture polystyrene. 
ylene, polyurethane, and tissue culture polystyrene. 
It was evident hat human umbilical vein endothelial 
cells grown on polytetrafluoroethylene a d polyure- 
thane, respectively, released significantly more plas- 
minogen activator inhibitor-1 and tissue-type plas- 
minogen activator into the conditioned medium 
(plasminogen activator inhibitor-l: polytetrafluoro- 
ethylene, 2.51 _+ 0.31 /xg/105 cells per 24 hours; 
polyurethane, 2.24 _ 0.16/~g/105 cells per 24 hours; 
tissue culture polystyrene, 0.72 + 0.10/xg/105 cells 
per 24 hours; p < 0.001 for polytetrafluoroethylene 
and polyurethane compared with tissue culture poly- 
styrene; tissue-type plasminogen activator: polytet- 
rafluoroethylene: 13.8 _+ 1.5 ng/10 s cells per 24 
hours; polyurethane, 15.4 + 1.2 ng/10 s cells per 24 
hours; tissue culture polystyrene, 7.7 _+ 1.1/105 cells 
per 24 hours; p < 0.001 for polytetrafluoroethylene 
and polyurethane as compared with tissue culture 
polystyrene). Urokinase-type plasminogen activator 
antigen was not detected in the conditioned medium 
under the conditions tested (Fig. 4). 
As can be seen from Fig. 5, human umbilical vein 
endothelial cells grown on polytetrafluoroethylene 
deposited significantly more plasminogen activator 
inhibitor-1 antigen into the extracellular matrix than 
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Fig. 3. Cell number and time course of tissue-type plas- 
minogen activator antigen production by human umbilical 
vein endothelial cells grown on polytetrafluoroethylene. 
Human umbilical vein endothelial cells were seeded at a 
density of 9 × 103/cm 2 onto polytetrafluoroethylene 
coated with fibronectin (10 tzg/cm2). Cell numbers (open 
circles) at the days indicated and tissue-type plasminogen 
activator antigen (closed circles) in the conditioned me- 
dium harvested at the days indicated were determined as 
described in the Materials and methods ection. Values 
represent means _+ standard eviations of three indepen- 
dent experiments. Twelve pieces of the biomaterials were 
used. t-PA, Tissue-type plasminogen activator. 
tissue culture polystyrene (p < 0.01). No tissue-type 
plasminogen activator could be detected in the 
extracellular matrix of human umbilical vein endo- 
thelial cells grown under these conditions. 
Discussion 
Endothelium on vascular grafts has been shown to 
diminish platelet deposition and to improve the 
patency of prostheses, s' 24, 25 However, adhesion and 
proliferation of endothelial cells on pure graft ma- 
terials is minimal)' 26 Fibronectin and fibrin glue 
have been used to coat biomaterials to enhance 
adhesion and proliferation of endothelial cells. We 
could demonstrate hat proliferation of human um- 
bilical vein endothelial cells increased in a dose- 
dependent fashion when seeded onto polytetraflu- 
oroethylene coated with increasing concentrations 
of fibronectin. The binding capacity for fibronectin 
of the two biomaterials used, namely polytetraflu- 
oroethylene and polyurethane, was similar. Prolifer- 
ation of human umbilical vein endothelial cells, 
however, was significantly higher on polyurethane 
than on polytetrafluoroethylene. Thiswas also true 
when proliferation of human umbilical vein endo- 
thelial cells was measured on untreated polyure- 
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Fig. 4. Plasminogen activator inhibitor-1 and tissue-type 
plasminogen activator antigen secreted by confluent 
monolayers of human umbilical vein endothelial cells 
grown on polytetrafluoroethylene, polyurethane, and tis- 
sue culture polystyrene. Human umbilical vein endothelial 
cells were grown to confluence on polytetrafluoroethyl- 
ene, polyurethane, or tissue culture polystyrene coated 
with fibronectin (10/zg/cm2). Plasminogen activator inhib- 
itor-1 and tissue-type plasminogen activator antigen in the 
conditioned medium of such cells incubated for 24 hours 
were determined by specific ELISAs, as described in the 
Materials and methods section. Significantly more plasmin- 
ogen activator inhibitor-1 antigen and tissue-type plasmin- 
ogen activator antigen were produced by human umbilical 
vein endothelial cells grown on polyurethane and polytet- 
rafluoroethylene, r spectively, as compared to human 
umbilical vein endothelial cells grown on tissue culture 
polystyrene (*p < 0.001). Values represent means - 
standard eviations of three independent experiments. 
Twelve pieces of the biomaterials were used. PAI-1, 
Plasminogen activator inhibitor-i; t-PA, tissue-type plas- 
minogen; TCP, tissue culture polystyrene; PU, polyure- 
thane; PTFE, polytetrafluoroethylene. 
thane and polytetrafluoroethylene. The latter result 
could be explained by the fact that polyurethane 
provides a smooth surface for endothelial cell at- 
tachment whereas polytetrafluoroethylene shows a 
nodular structure. 1' 27 
The fibrinolytic system of human umbilical vein 
endothelial cells grown on artificial graft materials 
was chosen as a marker of functional integrity of 
these cells because it plays a major role in the 
development and dissolution of intravascular fibrin 
clots. Therefore functional integrity of the fibrino- 
lytic system of endothelial cells seeded onto vascular 
grafts might contribute to the maintenance of a 
nonthrombogenic surface of the prostheses. We 
could demonstrate hat human umbilical vein endo- 
thelial cells grown on polytetrafluoroethylene or 
polyurethane produce tissue-type plasminogen acti- 
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Fig. 5. Plasminogen activator inhibitor-1 antigen depos- 
ited by human umbilical vein endothelial cells grown on 
polytetrafluoroethylene or tissue culture polystyrene, re- 
spectively, into the extracellular matrix. Human umbilical 
vein endothelial cells were grown to confluence on poly- 
tetrafluoroethylene or tissue culture polystyrene coated 
with fibronectin (10/xg/cm2). Plasminogen activator inhib- 
itor-1 antigen deposited into the extracellular matrix by 
such cells incubated for 24 hours was determined by a 
specific ELISA as described in the Materials and methods 
section. Human umbilical vein endothelial cells grown on 
polytetrafluoroethylene deposited significantly more plas- 
minogen activator inhibitor-1 antigen in the extracellular 
matrix than did human umbilical vein endothelial cells 
grown on tissue culture polystyrene (p < 0.01). Values 
represent means 2 standard eviations of three indepen- 
dent experiments. Fifteen pieces of the biomaterials were 
used. PAL1, Plasminogen activator inhibitor-i; ECM, 
extraceUular matrix; TCP, tissue culture polystyrene; 
PTFE, polytetrafluoroethylene. 
vator and plasminogen activator inhibitor-i, respec- 
tively, the two major components of the fibrinolytic 
system produced by human umbilical vein endothe- 
lial cells when cultured under in vitro conditions on 
tissue culture plastic. It is, however, noteworthy that 
human umbilical vein endothelial cells grown on 
polytetrafluoroethylene or polyurethane, respeo. 
tively, produced significantly more tissue-type plas-- 
minogen activator and plasminogen activator inhib- 
itor-1 than did human umbilical vein endothelial 
cells grown as a control on tissue culture polysty.- 
rene. 
It has been suggested that activation of fibrinoly- 
sis by plasminogen activators produced by endothe- 
lial cells seeded onto vascular grafts would lead to 
the disintegration of fibrin layers coated onto the 
grafts to enhance endothelial cell attachment and 
subsequently to the dislodgment of these cells from 
such surfaces. 28' 29 In this study, however, we dem- 
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onstrate that human umbilical vein endothelial cells 
grown on polytetrafluoroethylene deposited signifi- 
cantly more plasminogen activator inhibitor-1 into 
the extracellular matrix than did human umbilical 
vein endothelial cells cultured on tissue culture 
polystyrene. Plasminogen activator inhibitor-1 de- 
posited into the extracellular matrix by endothelial 
cells has been shown to remain active and to be 
capable of inactivating tissue-type plasminogen ac- 
tivator by forming a stable complex with the plas- 
minogen activator. 3° Therefore one could speculate 
that plasminogen activator inhibitor-1 deposited 
into the extracellular matrix by human umbilical 
vein endothelial cells grown on artificial graft mate- 
rials might act to prevent proteolytic damage to the 
endothelial layer on vascular prostheses. 
In conclusion, our data emphasize the importance 
of precoating vascular graft materials with sub- 
stances uch as fibronectin, which enhance attach- 
ment and proliferation of endothelial cells on these 
materials. Furthermore, our results give evidence 
that endothelial cells grown on artificial surfaces 
used for the production of vascular grafts show 
functional integrity with respect o their fibrinolytic 
system. This fact might contribute to the decreased 
thrombogenicity of endothelialized grafts as com- 
pared with grafts without endothelial lining. Finally, 
the presence of plasminogen activator inhibitor-1 in 
the extracellular matrix of endothelial cells grown 
on artificial graft material suggests that the endo- 
thelial monolayer should be protected from proteo- 
lytic damage caused by plasminogen activators. 
We thank Renate Beckmann for providing fibronectin 
and Thomas Nardelli for preparing the figures. 
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